Clinical Trial

A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers

Completed Early Phase 1
View on ClinicalTrials.gov →
Summary
The main objective is to assess the safety and tolerability of subcutaneous and intravenous injection forms of budoprutug in healthy volunteers.
Protocol Amendment History 3 changes
critical Trial completed 2026-07-31
notable Enrollment reduced: 38 -> 30 participants 2026-07-31
minor Completion moved earlier: 2026-06 -> 2026-04-07 2026-07-31
Trial Details
NCT Number NCT07090655
Lead Sponsor Climb Bio, Inc.
Conditions Healthy Volunteers
Enrollment 30 participants
Start Date 2025-08-11
Primary Completion 2026-04-07 (estimated)
Study Completion 2026-04-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-30